Article Text

Download PDFPDF

Foxp3 expression in breast cancer patient from Qatar: survival analysis
  1. Mahmoud G Mohamed1,2,
  2. Hina Sarwath1,
  3. Shaykha Alqahtani1,
  4. Salha Bujjasoum2,
  5. Imad Bin Mujeeb2,
  6. Mufeed Almesteri2,
  7. Hikmat Bugrein2,
  8. Prem Chandra2 and
  9. Shahinaz Bedri1
  1. Aff1 grid.416973.e0000000405824340ResearchWeill Cornell Medical College in Qatar Doha Qatar
  2. Aff2 grid.413548.f000000040571546XHamad Medical Corporation Doha Qatar

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts

In breast cancer, the presence of Foxp3 (Tregs) [1] within the tumor milieu has been a matter of debate. Some studies have determined that infiltration of Tregs was associated with poor survival, while others revealed no impact on survival, however this depends on their type, type of cells expressing Foxp3 and the density of the Tregs population [2].

The goal of our study was to quantify Foxp3 in breast cancer patients from Qatar and correlate with their survival.


Expression of FoxP3 was studied in 132 FFPE samples with known clinico-pathological data by immunohistochemistry technique and quantified by modified H-score system by pathologist. Results were analyzed via SPSS.


Analysis was carried for 132 patients. Age at time of diagnosis was 49 ±10.4 years. 76.2% of the patients showed positive expression of FoxP3. FoxP3 expression was not correlated with patient age or hormone receptors. Expression of Foxp3 positively correlate with better patient survival when compared to negative expression (94.1, 95% CI 85.6 - 102.6 versus 83.6, 95% CI 71.8 - 95.5, p 0.60).


FoxP3 is expressed on lymphocytes that are present in the tumor microenvironment regardless of breast cancer subtypes. Foxp3 is correlated with better survival.


  1. 1.
  2. 2.